MCM
ALT icon

MAI Capital Management’s Altimmune ALT Stock Holding History

MAI Capital Management’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-150
Closed -$462 – 2189
2026
Q1 		$462 Hold
150
– – ﹤0.01% 4435
2025
Q4 		$542 Hold
150
– – ﹤0.01% 3808
2025
Q3 		$566 Buy
+150
New +$579 ﹤0.01% 3599

Other funds holding ALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MAI Capital Management's ALT Position: Q2 2026 in Review

MAI Capital Management sold out of Altimmune (ALT) in Q2 2026, closing a stake of 150 shares — an estimated $462 sold.

MAI Capital Management first reported a position in ALT in Q3 2025 and held it in 3 quarters. The position peaked at $566 in Q3 2025. 210 funds tracked by Wall St. Rank hold ALT as of Q2 2026.

  • MAI Capital Management reported no remaining Altimmune position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 150 Altimmune shares in Q2 2026, an estimated $462.
  • MAI Capital Management first reported a position in Altimmune in Q3 2025 and held it in 3 quarters.
  • MAI Capital Management's Altimmune position peaked at $566 in Q3 2025.
  • 210 funds tracked by Wall St. Rank held Altimmune as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.